174 related articles for article (PubMed ID: 29410344)
1. Real-world evidence-What is it and does it matter for approval of drugs?
Eaglstein WH
J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
[No Abstract] [Full Text] [Related]
2. Real-world studies no substitute for RCTs in establishing efficacy.
Gerstein HC; McMurray J; Holman RR
Lancet; 2019 Jan; 393(10168):210-211. PubMed ID: 30663582
[No Abstract] [Full Text] [Related]
3. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.
Corrigan-Curay J; Sacks L; Woodcock J
JAMA; 2018 Sep; 320(9):867-868. PubMed ID: 30105359
[No Abstract] [Full Text] [Related]
4. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.
Wallach JD; Zhang AD; Skydel JJ; Bartlett VL; Dhruva SS; Shah ND; Ross JS
JAMA Netw Open; 2021 Nov; 4(11):e2133667. PubMed ID: 34751763
[TBL] [Abstract][Full Text] [Related]
5. Public-sector Contributions to Novel Biologic Drugs.
Nayak RK; Lee CC; Avorn J; Kesselheim AS
JAMA Intern Med; 2021 Nov; 181(11):1522-1525. PubMed ID: 34279545
[TBL] [Abstract][Full Text] [Related]
6. Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example.
Gross AM
Curr Probl Cancer; 2021 Aug; 45(4):100769. PubMed ID: 34247834
[TBL] [Abstract][Full Text] [Related]
7. A Call to Action to Track Generic Drug Quality Using Real-World Data and the FDA's Sentinel Initiative.
Brown JD
J Manag Care Spec Pharm; 2020 Aug; 26(8):1050. PubMed ID: 32715968
[TBL] [Abstract][Full Text] [Related]
8. Innovative design and analysis for rare disease drug development.
Chow SC; Huang Z
J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
[TBL] [Abstract][Full Text] [Related]
9. Paying for Cancer Drugs That Prove Their Benefit.
Frank RG; Emanuel EJ
JAMA; 2021 Oct; 326(16):1579-1580. PubMed ID: 34633420
[No Abstract] [Full Text] [Related]
10. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
Peck CC; Rubin DB; Sheiner LB
Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
[No Abstract] [Full Text] [Related]
11. A proposal for radical changes in the drug-approval process.
Wood AJ
N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
[No Abstract] [Full Text] [Related]
12. [The long path (s) of placing medicines on the market].
Duguet C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
[No Abstract] [Full Text] [Related]
13. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
14. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
Schilsky RL
J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
[No Abstract] [Full Text] [Related]
15. Two-stage drug approval would reduce the risks.
Frantz JA
Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
[No Abstract] [Full Text] [Related]
16. Accelerated approval of oncology drugs: can we do better?
Ellenberg SS
J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
[No Abstract] [Full Text] [Related]
17. The use of real-world data in cancer drug development.
Skovlund E; Leufkens HGM; Smyth JF
Eur J Cancer; 2018 Sep; 101():69-76. PubMed ID: 30031168
[TBL] [Abstract][Full Text] [Related]
18. The generic drug approval process.
Rheinstein PH
Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
[No Abstract] [Full Text] [Related]
19. Faster evaluation of vital drugs.
Kessler DA; Feiden KL
Sci Am; 1995 Mar; 272(3):48-54. PubMed ID: 7871409
[No Abstract] [Full Text] [Related]
20. Clinical trials and tribulations. Spiraling costs threaten gridlock.
Malakoff D
Science; 2008 Oct; 322(5899):210-3. PubMed ID: 18845742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
